A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer.

Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...

By binding to CTLA4, which is a key negative regulator of T-cell activation, ipilimumab (developed by Medarex in conjunction with Bristol-Myers Squibb) acts to potentiate the immune response ...

LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...